Obesity and metabolic drug pipelines

Genentech pays Hanmi 2.5 times Lilly's upfront for an asset one trial phase behind

Two out-licensing deals in three months put 375.8 billion won of upfront cash on Hanmi's books, about 1.5 times last year's operating profit, and it was the obesity candidate still in Phase 1 that priced richest.